Most plans that cover Zepbound (tirzepatide) will not pay for the first box until a prior authorization clears. Approval usually turns on three things: a diagnosis your plan accepts, a body mass index at or above its threshold, and chart notes showing you have done what the plan asks first. The form, the wait and the appeal all follow from those three.
Prior authorization for Zepbound is a payment decision, not a clinical one. Your prescriber decides the medicine is appropriate. Your plan decides whether it pays under your pharmacy benefit. Knowing which of those two is blocking you saves weeks of phone calls.
Is Zepbound covered with a prior authorization, or excluded outright?
These two problems look identical at the pharmacy counter, and they are not the same. A drug that is covered with prior authorization can be approved once the paperwork lands. A drug your employer has carved out of the benefit will not be approved through the normal review, no matter how strong the notes are.
Two questions to member services settle it:
- Is tirzepatide on my plan’s drug list, and on which tier?
- Does my pharmacy benefit exclude drugs used for weight management?
If weight management is excluded, your route is a formulary exception request, a benefits conversation with your employer at renewal, or paying cash. If Zepbound sits on the drug list with a PA flag next to it, the rest of this article is your path.
Why it matters: a weight management exclusion is written into the plan document, so appeals built on medical necessity alone rarely move it.
What diagnosis is needed for Zepbound?
The FDA label sets the outer boundary, and plan criteria rarely go wider than it. Zepbound is approved for adults for chronic weight management with a reduced calorie diet and increased physical activity, in people with obesity (a BMI of 30 or higher) or a BMI of 27 or higher plus at least one weight related condition. Those conditions include high blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnea and cardiovascular disease. A second indication covers moderate to severe obstructive sleep apnea in adults with obesity.
Reviewers do not read paragraphs, they read codes and numbers. A clean submission usually carries an obesity code such as E66.01 or E66.9, a BMI code from the Z68 series, and a code for the qualifying condition, for example I10 for hypertension, E11.9 for type 2 diabetes, E78.5 for dyslipidemia or G47.33 for obstructive sleep apnea. If the BMI is between 27 and 30, the comorbidity code is doing the heavy lifting, so it needs supporting evidence in the record: a blood pressure log, an A1c or lipid panel, or a sleep study report.
Check where your number falls before the appointment, because the threshold decides which set of criteria applies to you.
BMI calculator
Most weight-loss programmes screen on BMI before they will prescribe. This is the number they will use.
A screening number, not a diagnosis. It does not distinguish muscle from fat, and it reads high for muscular builds.
One detail trips people up. The BMI that counts is the documented one in the chart, usually a recent office measurement, and some plans also want a baseline weight from an earlier visit. Home scale readings and a number you calculated yourself do not substitute for a measured height and weight in the record.
Zepbound prior authorization criteria: the checklist reviewers work from
Criteria differ by plan, but the same items show up again and again. Treat this as the list to have ready, then confirm the exact wording in your own plan’s coverage policy.
- Age. Adult use, 18 and older, is the standard boundary for the weight management indication.
- Documented BMI. A measured height and weight in the chart, with the qualifying threshold met, and often a baseline weight for later renewal comparisons.
- A qualifying condition when BMI is 27 to 29.9. Named diagnosis plus the lab, reading or study that backs it.
- Lifestyle documentation. Many plans ask for evidence of a reduced calorie diet and increased activity, sometimes for a set period such as three to six months, and sometimes through a specific program the plan sponsors.
- Step therapy. Some plans require a trial of a preferred agent first, or documentation that it failed, was not tolerated or was contraindicated.
- No duplicate therapy. An attestation that you are not taking another GLP-1 or GIP/GLP-1 medicine at the same time, and are not using Zepbound alongside Mounjaro.
- Prescriber type. A few plans want the request from, or endorsed by, a specialist.
- Quantity limit. Approval is typically written for a set number of pens or vials per 28 or 30 days, matching label dosing.
Step therapy is the criterion most worth reading closely. If your plan lists a preferred alternative, the fastest path is often a documented trial of it, or a clear contraindication note, rather than an argument about why Zepbound should be first. Prior side effects, pregnancy plans, thyroid history and personal or family history of medullary thyroid carcinoma are all things the prescriber should record when they apply, because Zepbound carries a boxed warning for thyroid C-cell tumors and is contraindicated with a personal or family history of medullary thyroid carcinoma or with MEN 2.
The Zepbound prior authorization form, and who actually files it
There is no single national form. The form belongs to your plan or its pharmacy benefit manager, and most reviews now run through electronic prior authorization inside the prescriber’s e-prescribing software instead of a fax.
- Confirm the requirement. Search the drug list in your member portal, or call the number on your card, and note whether it says PA, ST (step therapy) or QL (quantity limit).
- Ask the plan where the form lives, or ask your prescriber’s office to submit through electronic prior authorization.
- Gather the record before submission: measured height and weight with dates, the coded diagnosis, comorbidity evidence, prior medication trials with dates and outcomes, and lifestyle notes.
- Submit and write down the reference number, the date and the name of the person or system that took it.
- Follow up in three business days. Incomplete requests sit in a queue instead of being denied, and nobody calls to tell you.
Whoever writes the prescription owns the submission, so it is fair to ask how much of this a practice does routinely. Clinics that treat obesity all day usually have templated notes and a staff member who handles benefit reviews, which is often the difference between a first pass approval and three rounds of requests for more information.
PA Submission Checklist for Zepbound
- Confirmed tirzepatide is on plan formulary (not excluded for weight management)
- Measured height, weight, and BMI documented in chart with date
- Obesity or qualifying comorbidity diagnosis coded (E66.x, Z68.x, I10, E11.9, etc.)
- Lab or study supporting comorbidity (A1c, lipid panel, sleep study) in record
- Step therapy requirement met: prior agent trial documented with dates and outcome
- Lifestyle intervention (diet/activity) documented for required period
- No concurrent GLP-1 or GIP/GLP-1 therapy noted
- Reference number, date, and contact recorded after submission
No provider matches that filter. .
See every provider we track, with filters and sorting
How long a Zepbound prior authorization takes
Timelines are set by rule, not by goodwill, and they differ by benefit type. In employer sponsored plans, a non urgent request for care that needs pre-approval must be decided within 15 days, and an urgent request within 72 hours (29 CFR 2560.503-1). For Medicare drug coverage, a standard coverage determination is due within 72 hours and an expedited one within 24 hours (42 CFR Part 423).
In practice, a complete electronic submission with clean documentation often comes back in a few business days. Requests that stall usually stall for one of two reasons: the plan asked for more information and the clock restarted, or the submission went to the medical benefit when it belonged in the pharmacy benefit. If you are past the outer limit with no answer, say the words “I am filing a complaint about the decision timeline” and ask for it in writing. That tends to unstick a queue faster than another status call.
Why insurance will not approve Zepbound, and how to push back
Denial letters are short, but the reason code tells you what to fix. The common ones:
- BMI not documented, or documented below the threshold that applies.
- A BMI of 27 to 29.9 with no coded, evidenced comorbidity.
- Step therapy not satisfied, with no record of a preferred agent trial.
- No lifestyle intervention documented, or none for the required length of time.
- The plan excludes weight management drugs entirely, so no criteria were even applied.
- Quantity or dose requested does not match the approved titration schedule.
- Missing signature, wrong form, or the request filed under the wrong benefit.
The appeal ladder is more forgiving than it looks, and most of it is free.
Appeal Path After a Zepbound Denial
- Read the denial reason code to identify exactly what is missing
- Fix and resubmit if the denial is documentation-based (faster than a formal appeal)
- File an internal appeal within the deadline, attaching the specific evidence the reason code requested
- Request a peer-to-peer review between your prescriber and the plan's reviewing clinician
- Submit a formulary exception if the drug is off-list or non-preferred
- Escalate to external independent review if internal appeals are exhausted
- Fix and resubmit. If the denial is documentation based, a corrected submission is faster than a formal appeal.
- Internal appeal. File within the deadline on the letter, and attach the specific evidence the reason code asked for.
- Peer to peer review. Your prescriber speaks with the plan’s reviewing clinician. Ask for it by name.
- Formulary exception. Use this when the drug is off the list or non preferred, and argue why the preferred alternatives are not appropriate for you.
- External review. In most commercial plans an independent organization can overturn the plan. In Medicare, the next step after redetermination goes to an independent review entity.
Keep every letter, date and reference number in one place. Appeals are won on dated records more often than on wording.
Where the criteria live, plan by plan
Naming the right document is half the work. Criteria are published, and reading yours beats guessing from someone else’s approval story.
| Plan or benefit manager | Where to look | What to ask for |
|---|---|---|
| Express Scripts | Member portal drug list plus the published coverage policy | The tirzepatide criteria sheet and any step therapy list |
| CVS Caremark | Plan specific formulary and criteria documents in the member account | Whether weight management is included in your employer’s benefit |
| Blue Cross Blue Shield and Anthem plans | Local plan medical or pharmacy policy library | The prior authorization criteria document for the anti obesity class |
| UnitedHealthcare | Prescription drug list plus the pharmacy provider resource library | Whether new starts and expired approvals both need review |
| Cigna | Plan drug list and coverage policy for weight management agents | Renewal criteria and the required weight loss threshold |
| TRICARE | Formulary search tool run through the pharmacy contractor | The current form and any required lifestyle documentation |
| Medicare and Medicaid | Part D plan formulary, or your state Medicaid preferred drug list | Which indication the plan will pay for |
Medicare deserves its own line. Part D has long excluded drugs used for weight loss from covered Part D drugs, which is why a straightforward obesity request is often refused outright. Coverage can change when the same drug is prescribed for another medically accepted indication, which is where the sleep apnea use becomes relevant. State Medicaid programs set their own rules and several cover anti obesity agents with prior authorization, so the answer depends on your state’s preferred drug list rather than on national policy.
What approval is worth, and what a denial costs you
Approval does not mean free. A plan can place Zepbound on a high tier with coinsurance instead of a flat copay, apply the deductible first, or cap the fill at 28 days. Ask three specific questions once the approval lands: which tier, copay or coinsurance, and does the deductible apply. A 25 percent coinsurance on a high list price drug behaves very differently from a fixed copay.
Manufacturer savings support exists for many commercially insured patients and self pay purchasing exists for single dose vials, both of which change the arithmetic when a plan says no. Across the self pay clinicians we track, tirzepatide programs run from about $99 to $399 a month, with a median near $202.
Run your own numbers before you commit to fighting a denial for six months, because sometimes the cash route costs less than the coinsurance on an approved claim.
Insurance or cash pay, which is cheaper
Going through insurance is not automatically cheaper. Deductibles, copays and prior authorisation can make a cash-pay programme the better deal.
Coverage is never something a programme can promise: plans decide, prior authorisation is routine for GLP-1 medicines, and denials are common. Confirm with your own plan before choosing.
If you do end up paying yourself, price is only one of the variables. Titration support, refill logistics and how a practice handles paperwork all matter over a year of treatment.
Lowest monthly price
Cheapest verified plan for a new self-pay patient.
- Amazon One Medical$17/mo
- LifeMD$19/mo
- PlushCare$20/mo
- Hims$22/mo
- Strut Health$25/mo
Best on accessibility
Who can actually get seen, and how fast.
- Zealthy9 / 10
- Found9 / 10
- Teladoc Health8.8 / 10
- LifeMD8.5 / 10
- Amazon One Medical8 / 10
Ranked from our own scores, recomputed as data changes. Providers cannot pay for a place.
Renewal: what keeps coverage in place after the first approval
Approvals are written for a set period, commonly six or twelve months, and then they expire. Reauthorization criteria usually ask for two things: evidence that you are still taking the medicine as prescribed, and evidence that it is working. Many plans set a documented weight loss threshold, often around 5 percent of starting body weight, and compare a fresh measured weight against the baseline in your chart.
That makes the baseline weight the single most valuable number in your record. If it was never documented properly, renewal becomes an argument. Ask at your first visit that the starting weight and date be recorded, then keep every follow up weight in the same chart rather than across three different clinics.
If progress has slowed, your prescriber can document other measured benefits: blood pressure, A1c, lipids, sleep apnea severity or waist circumference. Plans that use a weight based renewal rule still read the rest of the note, and a plateau with maintained loss reads differently from no response at all.
Prior authorization for Zepbound for sleep apnea
This is a separate review with a separate evidence set. The obstructive sleep apnea indication covers adults with moderate to severe OSA and obesity, so a plan reviewer will look for both parts: the obesity documentation described above, and objective sleep testing.
That usually means a sleep study report with an apnea hypopnea index in the moderate to severe range, coded as G47.33, plus notes on current treatment such as positive airway pressure use, tolerance or refusal. The label does not require that a device has failed, but individual plans can ask about it, so record the history either way.
The practical reason this route matters is benefit design. Where a plan excludes weight loss drugs but covers treatments for diagnosed sleep apnea, the sleep apnea indication can be the only door that opens. It has to be the honest clinical reason for the prescription, and the sleep study has to exist.
What to do next
- Search your plan’s drug list for tirzepatide and note the tier and the PA, ST or QL flags.
- Ask member services whether weight management drugs are excluded from your pharmacy benefit.
- Download your plan’s coverage criteria document and read the renewal section as well as the initial one.
- Book a visit where the measured height, weight, BMI and any comorbidity evidence are recorded on the same day.
- Have the prescriber submit electronically, then confirm receipt in three business days.
- If it is denied, read the reason code first, and choose between resubmission, internal appeal, peer to peer or an exception request based on what the code says.
Authoritative sources
- FDA approval announcement for chronic weight management
- FDA announcement on the obstructive sleep apnea indication
- Medicare drug coverage rules and exceptions
- Manufacturer access and coverage information
This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified clinician or pharmacist about your situation, and seek urgent care or call your local emergency number for severe or worsening symptoms.
